Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD study of CNM-Au8 in healthy volunteers
NL-OMON42813Phase 1Active, not recruiting
- Sponsor
- Clene Inc.
- Start
- Apr 2015
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuromyelitis optica (NMO) and demyelinating disease comparing CNM-Au8 with Placebo (2 arms). Primary endpoints: SAD pharmacokinetics, MAD pharmacokinetics and 1 more. Started Apr 2015; status: active, not recruiting.
02
Drugs
CNM-Au8
03
Conditions
neuromyelitis optica (NMO)demyelinating disease
Beyond the preview
Go deeper on NL-OMON42813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42813.